Artiva Biotherapeutics, Inc.

Artiva Biotherapeutics announced that its Compensation Committee approved inducement grants covering an aggregate of 288,800 restricted stock units (RSUs) for 17 new employees. These grants, effective July 14, 2026, were made pursuant to Artiva’s 2025 Inducement Plan. The RSUs will vest over four years, subject to the employee’s continued employment, and were granted as material inducements for employment in accordance with Nasdaq listing Rule 5635(c)(4).

Artiva Biotherapeutics announced that its management will participate in a fireside chat at the H.C. Wainwright 4th Annual Cell Therapy Virtual Conference on June 30, 2026, at 3:30 pm EDT. An audio webcast and archived recording will be accessible via the Investors section of Artiva's website for 90 days. The company is a clinical-stage biotechnology firm developing cell therapies for autoimmune diseases, with its lead program AlloNK (AB-101) slated for a Phase 3 trial in refractory rheumatoid arthritis in 2026.

Artiva Biotherapeutics announced that its lead candidate, AlloNK (AB-101) combined with rituximab, received Regenerative Medicine Advanced Therapy (RMAT) designation from the FDA for refractory rheumatoid arthritis (RA). This designation supports an expedited development and review process. The company also presented robust clinical, safety, and translational data at the EULAR 2026 Congress, demonstrating deep B-cell depletion and meaningful clinical responses across RA, Sjögren disease, and systemic sclerosis. With an extended cash runway into 2029, Artiva is well-positioned to advance its planned Phase 3 trial in refractory RA.

Artiva Biotherapeutics announced that its management will participate in a fireside chat at the 2026 Jefferies Global Healthcare Conference on Thursday, June 4, 2026, at 9:20 am EDT. The company, a clinical-stage biotechnology firm, is focused on developing effective, safe, and accessible cell therapies for patients with debilitating autoimmune diseases. Its lead program, AlloNK (AB-101), is currently being evaluated in three ongoing clinical trials for B-cell driven autoimmune diseases, with plans to initiate a Phase 3 registrational trial in refractory RA in 2026.

Artiva Biotherapeutics announced upcoming data presentations at the European Alliance of Associations for Rheumatology (EULAR) 2026 Congress, highlighting positive clinical responses for its AlloNK + rituximab therapy. The data showed efficacy comparable to autologous CAR T-cell therapy in 31 patients with rheumatologic diseases, including a 71% ACR50 response in refractory rheumatoid arthritis patients with no relapses. The therapy also demonstrated deep B-cell depletion and a favorable safety profile. Artiva plans to initiate a Phase 3 registrational trial for AlloNK in refractory RA in 2026.

Artiva Biotherapeutics announced several leadership changes, including the departure of its Chief Financial Officer, Thad Huston, effective May 22, 2026. Concurrently, Dr. Diego Miralles resigned from the Board to assume the role of President and Head of Research and Development. Dr. Fred Aslan, who resigned as President, will continue as CEO and Board member, and has been appointed principal financial and accounting officer. Mr. Huston will receive a severance package including a $135,000 cash payment and COBRA benefits, while Dr. Miralles's new compensation includes a $600,000 annual salary, a 45% target bonus, and equity awards.

Artiva Biotherapeutics, Inc. announced the appointment of Diego Miralles, M.D., as President and Head of Research and Development. Dr. Miralles brings over two decades of senior leadership and drug development experience, with a proven track record of advancing therapies from discovery through FDA approval and commercialization. His expertise will be crucial as Artiva advances its lead program, AlloNK®, in autoimmune diseases and prepares for a Phase 3 registrational trial in refractory rheumatoid arthritis in 2026, with a goal to file the first BLA for AlloNK in 2029. In connection with his appointment, Dr. Miralles received an inducement grant of options to purchase 232,500 shares and 77,500 restricted stock units.

Artiva Biotherapeutics, Inc. entered into an underwriting agreement to issue and sell 23,871,526 shares of common stock at $11.52 per share and pre-funded warrants to purchase 2,170,138 shares at $11.5199 per warrant. The offering is expected to generate approximately $300.0 million in gross proceeds for the company. The closing of the offering is anticipated on May 11, 2026, subject to customary conditions.

Artiva Biotherapeutics, a clinical-stage biotechnology company, announced the pricing of an underwritten offering of common stock and pre-funded warrants. The offering includes 23,871,526 shares of common stock at $11.52 per share and 2,170,138 pre-funded warrants at $11.5199 per share. The company expects to raise approximately $300 million in gross proceeds from the offering, which saw participation from several institutional investors and is slated to close around May 11, 2026.

Artiva Biotherapeutics reported an increased net loss for Q1 2026, reaching $(23.5) million, up from $(20.3) million in Q1 2025. The company's cash, cash equivalents, and investments decreased to $86.8 million as of March 31, 2026, from $108.0 million at December 31, 2025. Artiva continues to focus on developing NK cell-based therapies, with its lead candidate AlloNK in clinical development, and anticipates needing additional funding beyond Q2 2027 to support its operations.